CD55

CD55 詳細

英語名Complement decay-accelerating factor市販薬剤の数0
治験薬の数3ターゲットの別称DAF,Complement decay-accelerating factor,CD55,CD55 Molecule (Cromer Blood Group),CD55 Molecule, Decay Accelerating Factor For Complement (Cromer Blood Group),CD55 Antigen,CR,Decay Accelerating Factor For Complement (CD55, Cromer Blood Group System),Cromer Blood Group Antigen,CHAPLE,CROM,TC,CD55 Antigens
研究&開発段階Phase 2 Clinical
英語名Complement decay-accelerating factor
ターゲットの別称DAF,Complement decay-accelerating factor,CD55,CD55 Molecule (Cromer Blood Group),CD55 Molecule, Decay Accelerating Factor For Complement (Cromer Blood Group),CD55 Antigen,CR,Decay Accelerating Factor For Complement (CD55, Cromer Blood Group System),Cromer Blood Group Antigen,CHAPLE,CROM,TC,CD55 Antigens
市販薬剤の数0
治験薬の数3
研究&開発段階Phase 2 Clinical

CD55 製品リスト

  • 属性

    Protein (2)

  • 製品ライブラリ

    オンライン (2)

  • Human (2)

  • タグ

    His Tag (1)His Tag & Avi Tag (1)

  • マーカー

    Unconjugated (1)Biotin-labeled (1)

製品番号発現システム製品説明タンパク質の構造純度特性
CD5-H5225
Human
HEK293
Human CD55 / DAF Protein, His Tag, low endotoxin
CD5-H82E4
Human
HEK293
Biotinylated Human CD55 / DAF Protein, His,Avitag™ (MALS verified)
総数量2
  • 1

CD55バックグランド

CD55 is also known as DAF or decay­accelerating factor, is a member of the RCA (regulators of complement activation) family characterized by four to 30 SCRs (short consensus repeats) in their plasma-exposed regions. CD55 /DAF is a 70 kDa membrane protein that regulates the complement system on the cell surface. It prevents the assembly of the C3bBb complex (the C3-convertase of the alternative pathway) or accelerates the disassembly of preformed convertase, thus blocking the formation of the membrane attack complex. This glycoprotein is broadly distributed among hematopoietic and non-hematopoietic cells. It is a determinant for the Cromer blood group system. CD55 is known to bind CD97 via the first SCR. It also binds physiologically­generated C3 convertases with its second and third SCRs. Binding results in an accelerated “decay”, or dissociation of active C3 convertases, thus blocking the development of C’ attack complexes on nonforeign cells. Finally, viruses and bacteria are also known to utilize multiple SCR sites for infection.

CD55分子の別称

CD55,DAF,CR,CROM,TC

治験薬に関する情報

英語名研究コード研究開発ステージ会社適応症臨床試験
GebasaxturevV-937; CVA-21Phase 2 ClinicalViralytics LtdBreast Neoplasms; Head and Neck Neoplasms; Melanoma; Neoplasm Metastasis; Prostatic Neoplasms; Urinary Bladder Neoplasms
詳細
PAT-SC1SC-1; PAT-SC1; PAT-SC-1Phase 2 ClinicalOncomab GmbhStomach Neoplasms
詳細
Recombinant coxsackievirus B3Phase 1 ClinicalWuhan Boweid Biotechnology Co LtdNeoplasms
詳細
  • 詳細
  • 製品リスト
  • 治験薬に関する情報
お問い合わせ

お問い合わせ
グローバル:+1 800-810-0816(Toll Free)

メールアドレス
order.jp@acrobiosystems.com

アクロバイオシステムズ株式会社
〒101-0051
東京都千代田区神田神保町1-32-8